News FDA panel narrowly backs heart benefit of BI/Lilly diabetes ... FDA advisers voted 12-11 that Jardiance also reduces cardiovascular risks.
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Pharma looking to dual-action diabetes drugs to boost sales Pharma using FDA-mandated trials to give a commercial advantage.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.